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The great majority of membrane-associated antigens detected on neoplastic 
lymphoid cells in man lack tumor specificity (1), but, in B cell malignancies, Ig 
idiotypes represent true clonal-specific markers. While this property has allowed 
antiidiotype-specific monoclonal antibodies to be used in the treatment (2) of B 
cell tumors, the potential value of these antibodies is limited to individual patients. 
In  this  paper,  K-l-21,  a  monoclonal  antibody  with  a  broader  spectrum  of 
reactivity, is described.  It binds to free monomers and dimers of human kappa 
light chains,  not to intact  Ig molecules. K-l-21  also binds to plasma cells from 
patients with kappa myeloma but does not react with normal lymphoid cells nor 
to cells from other malignancies.  Thus the K-1-21-reactive determinant,  desig- 
nated  KMA  (kappa  myeloma antigen),  can  be regarded  as a  tumor-associated 
antigen with selectivity for kappa myeloma cells. 
Materials and Methods 
Human Serum and Urinary Proteins.  Serum albumin was obtained from Miles Labora- 
tories Inc., Elkhart, IN. Bence Jones protein (BJP) pools were purchased from Common- 
wealth Serum Laboratories, Melbourne, Australia. Kappa (NAP and VOR) and lambda 
(MOS) BJP, IgA paraproteins, and normal human IgG were purified by ion exchange and 
gel filtration chromatography. Periodic acid-treated VOR kappa BJP were prepared by 
the method of Shapiro and Erickson (3). 
Production and Purification of  K-I-21.  Spleen cells from BALB/c mice hyperimmunized 
with purified NAP kappa BJP were fused with P3-NSI-I-Ag4-1 (NS1) myeloma cells (4). 
One cloned hybrid, K-l-21, secreted a monoclonal IgG1 kappa antibody, as indicated by 
isoelectric focusing and by immunodiffusion in agarose with anti-mouse Ig-typing reagents 
(Litton Bionetics Inc., Kensington, MD). Ascites fluid from K-1-21 tumor-bearing BALB/ 
c mice was collected and purified by affinity chromatography on NAP or VOR kappa 
chains conjugated to Sepharose CL-4B (Pharmacia, Uppsala, Sweden). 
Radioimmunoassay.  Hybrid culture supernatants or purified K-l-21  antibodies were 
assayed by indirect solid-phase radioimmunoassay (RIA) using light chains or Ig bound to 
the wells of polyvinyl chloride microtiter trays at  1 mg]ml.  In all assays,  an unrelated 
monoclonai IgG1 antibody was included as a control. Antibody binding was detected by 
the addition of  • I-rabbit anti-mouse Ig. 
Preparation of Cells for Immunofluorescent Staining.  Bone marrow aspirates and samples 
of peripheral  blood  were  obtained  from  patients  with  myeloma,  or  other  lymphoid 
malignancies at the time of routine biopsy. Normal peripheral blood was collected from 
laboratory workers,  while  normal  bone  marrow  aspirates  were  obtained  from  renal 
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transplant donors on routine pretransplant assessment.  Tonsillar tissue came from elective 
tonsillectomies while spleens came from patients undergoing surgery for traumatic rupture 
or immune thrombocytopenic purpura. Mononuclear cell (MNC) fractions were separated 
on Ficoll-Hypaque (specific gravity, 1.078). Cells from bone marrow aspirates were then 
depleted of adherent cells and washed repeatedly to remove any cytophilic Ig. 
Human  Cell Lines.  LICR LON/HMy2 (HMy2) came from the  Ludwig Institute of 
Cancer Research (LICR), London; JURKAT was obtained from Dr. J. Watson, Medical 
School, Auckland University, Auckland, New Zealand and other cell  lines came from 
LICR, Sydney. 
Surface hnmunofluorescent Staining.  Cells were suspended at 2 x  107 cells/ml in RPMI 
containing 0.02% (wt/vol) sodium azide (RPMI-NaN~).  Aliquots (100 •1)  were incubated 
(o) with 100 ul of a  1:10 dilution of fluorescein isothiocyanate (FITC)-sheep F(ab')2 anti- 
human Ig heavy or light chain specific antisera (Kallestad Laboratories, Inc., Austin, TX) 
or (b) with 100 ul of K-l-21 or control IgG monoclonal antibodies (at 1 mg/ml) followed 
by 100 IA of a  1:50 dilution of FITC-sheep F(ab')~ anti-mouse Ig (New England Nuclear, 
Boston, MA). All incubations were for 30 min at 4°C followed by two washes with cold 
RPMI-NaN3.  Stained cells were resuspended in 10% phosphate-buffered saline (PBS) in 
glycerol, pH 8.6, and mounted for examination under a Zeiss photomicroscope II (Carl 
Zeiss, Oberkochen, Federal Republic of Germany). 
Fluorescence-activated Cell Sorter (FACS) III Analysis.  Aliquots of washed HMy2 cells (2 
X  10  6 cells in  100 #1) were exposed for 30 min at 4°C to 50 #g of K-l-21 alone or to K- 
1-21 preincubated with 620  ug VOR or MOS BJ  Proteins or to  1,820  t~g of normal 
human IgG. After washing twice in cold RPMI-NaN~,  the cells were incubated for 30 min 
at 4°C with  100 ul  FITC-sheep F(ab')~ anti-mouse Ig (New England Nuclear, Boston, 
MA) at a  1:50 dilution in PBS, pH 7.2.  After two washes in cold PBS-NaNs,  individual 
samples were analyzed on a FACS III (Becton, Dickinson & Co., Mountain View, CA). 
Results 
K-1-21 is a hybrid cell line secreting an IgG1 kappa monoclonal antibody that 
binds all free monomers and disulphide-bonded dimers of human kappa  light 
chains (Table I). No reactivity was seen with free lambda light chains, intact Ig 
molecules, or human serum albumin.  Binding was unaffected by periodic acid 
treatment  of the  antigen,  indicating  that  the  antibody  does  not  recognize  a 
carbohydrate determinant. 
The cell surface distribution of the K-l-21  reactive determinant, KMA, was 
examined by immunofluorescence of MNC  from normal  individuals and from 
patients  with  a  variety  of  B  or  T  cell  malignancies.  Two  IgG  monoclonal 
antibodies  of irrelevant  specificity were  used  as  controls and  always failed  to 
show any cell surface staining. 
K-1-21 antibody did not bind to the surface of normal MNC (Table II). It also 
failed to react with PBM from patients with kappa myeloma or to PBM or bone 
marrow plasma cells from patients with lambda myeloma and a  variety of non- 
myelomatous conditions, despite the presence  in  the latter samples  of varying 
numbers of plasma  cells reactive  with polyvalent anti-kappa  serum  (Table  II). 
On the other hand, plasma cells in bone marrow aspirates from eight out of 11 
patients with  kappa  myeloma showed strong fluorescent staining with K-l-21. 
The proportion of K-l-21-positive plasma cells varied greatly, ranging from 9 to 
78% of total plasma cells. Of the three cases where cells did not stain with K-l- 
21, two were IgG kappa myelomas and the third was an IgA kappa. While cells 
from one of the  IgG kappa  secretors also failed to react  with polyvalent anti- 
kappa or anti-Ig sera, anti-kappa antisera did stain 86 and 85%, respectively, of 
plasma  cells  from  the  remaining  two  patients.  Also,  BJP  from  these  patients BOUX  ET  AL.  BRIEF  DEFINITIVE  REPORT  1771 
TABLE  I 
Reactivity of K-l-21 with Various Human Serum and Urinary Proteins 
Protein  Reactivity with K- 1-21 
Serum albumin 
IgM kappa paraprotein 
lgA kappa paraprotein 
Normal lgG (pool) 
Normal light chain (pool) 
Lambda BJP (pool) 
Kappa BJP (pool) 
Purified lambda BJP 
Purified kappa BJP 
Purified dimers of kappa BJP 
Purified monomers of kappa BJP 
Periodic acid-oxidized VOR kappa BJP 
None 
None (0/2)* 
None (0/1) 
None 
Reactive 
None 
Reactive 
None (0/3) 
Reactive (10/10) 
Reactive (2/2) 
Reactive (2/2) 
Reactive (1 / 1) 
Binding of K-1-21  was assessed by indirect solid-phase RIA. Antigens 
tested were adsorbed onto polyvinyl plates. After blocking with bovine 
serum albumin, purified K-l-21  was added, followed by ~25I-rabbit anti- 
mouse Ig; radioactivity bound on each well was counted on a  gamma 
spectrometer. 
* Number reactive per number tested. 
TABLE  II 
Binding of K-l-21 to the Surface of Cells  from Normal Donors or Patients with Myeloma and 
Other Immunological Disorders 
Mononuclear  No. of  Reactivity with: 
Diagnosis  samples  cell source  tested  K- 1-21 *  Anti-kappa  s 
Peripheral blood  Normal  8  -  + 
B kappa CLL  3  -  + 
B lambda CLL  2  -  - 
Kappa myeloma  2  -  + 
Macroglobulinemia  1  -  + 
Sezary  2  -  + 
Multiple sclerosis  2  -  + 
T  CLL  2  -  + 
Tonsil  Normal  4  -  + 
Spleen  Normal  5  -  + 
Bone marrow 
Plasma cells only 
Normal  5  -  + 
Nonmyelomatous  0  5  -  + 
Myeloma 
IgG kappa  6  +  (4/6)  !  +  (5/6) 
lgG +  M kappa  1  +  + 
IgA kappa  2  +  (1/2)  +  (2/2) 
free kappa  2  +  (2/2)  +  (2/2) 
IgA lambda  1  -  ND  ~ 
free lambda  2  -  ND 
* Cells were stained with K-1-21 or a control monoclonal followed by FITC-sheep F(ab')2 anti-mouse 
Ig. 
s Cells were stained with FITC-goat anti-human kappa antiserum. The numbers of kappa-reactive 
cells fall within the expected normal range for each cell population examined. 
0 The five nonmyelomatous bone marrows were: amyloid of Ig origin (52% kappa-reactive plasma 
cells),  IgG  kappa  benign  paraproteinaemia  (50%  kappa),  systemic  lupus  erythrematosus  (40% 
kappa), B CLL in remission (18% kappa), and acute myeloid leukemia (12% kappa). 
! Number reactive per number examined. 
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TABLE  III 
Binding of K-l-21 Monoclonal Antibody to Determinants on the Surface 
of Various Human Cell Lines as Determined by Immunofluorescence 
Cell line  Cell line origin  Reactivity with 
K-I-21* 
LAZ-007  B cell ALL*  - 
RDG  B cell ALL  - 
WIL  B cell ALL  - 
JP  B cell, EBV transformed  a  - 
GK  B cell, EBV transformed  - 
SC4  B cell, EBV transformed  - 
Daudi  B cell, EBV transformed  - 
LICR LON/HMy2  IgG kappa myeloma  ++! 
PMC-22B  Melanoma  - 
CCRF-HSB  T  cell ALL  - 
F2/F7  T  cell ALL  - 
MPB ALL  T  cell ALL  - 
MOLT-4  T  cell ALL  - 
CCRF-CEM  T  cell pseudodiploid ALL  - 
JURKAT  T  cell leukemia  - 
* Cell lines were stained with K-l-21 or a control monoclonal followed by 
FITC-sheep F(ab')2 anti-mouse Ig. 
* ALL, acute lymphocytic leukemia. 
0 EBV, Epstein Barr virus. 
I Percentage of cells staining (10 experiments) ranged from 68 to 79%. 
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FIGURI~  1.  Single-parameter  histograms of FACS  III  analysis demonstrating the effect of 
preincubation with various immunoglobulin fractions on the binding of K-l-21  antibody to 
LICR LON/HMy2 cells. The cells (2 x  10  ~) were incubated with: (a) K-l-21 antibody alone, 
(b)  K-I-21  preincubated with VOR  kappa  BJP,  (c)  K-I-21  preincubated with  MOS lambda 
BJP, (d) K-l-21  preincubated with normal human IgG.  Labeled cells were then washed and 
incubated with F1TC-sheep F(ab')2 anti-mouse Ig before analysis on a  FACS  III. The high 
voltage and gain settings for all samples were identical. BOUX  ET  AL.  BRIEF  DEFINITIVE  REPORT  1773 
displayed strong reactivity with K-l-21  in an indirect RIA, indicating that a  K- 
I-21-reactive determinant was present on the secreted cell products. 
Further analysis of the KMA expression was carried out on human cell lines 
(Table  III).  Of these,  only HMy2,  derived from an  IgG  kappa  myeloma (5), 
reacted with K-l-21. 
The  specificity  of  K-l-21  binding  to  HMy2  cells  was  examined  by  flow 
cytometry. HMy2 cells were incubated with K-l-21 alone or with K-1-21 prein- 
cubated with normal human IgG or with lambda (MOS) or kappa (VOR) BJP. 
The cells were then  incubated with  FITC-sheep  F(ab')2 anti-mouse Ig.  Upon 
FACS analysis, HMy2 cells incubated with K-l-21  exhibited strong cell surface 
reactivity (Fig.  1).  However,  on exposure to  K-l-21  preincubated with  VOR 
kappa  light chains,  the fluorescence curve was shifted sharply to the left.  No 
apparent diminution in fluorescence intensity occurred when K-l-21  was prein- 
cubated with equivalent amounts of lambda light chain or with human IgG. 
Discussion 
The IgG~ monoclonal antibody K-l-21  described here recognizes an epitope 
on dimers and monomers of free human kappa light chains but fails to react with 
intact Ig.  Cell surface binding studies of K-1-21  antibody revealed an epitope, 
KMA, with tumor-specific properties. Thus, K-l-21 bound strongly to the surface 
of plasma cells from 8 of 11 patients with kappa myeloma but failed to react with 
plasma cells from normal individuals or from patients with lambda myeloma or 
nonmyeiomatous conditions.  Furthermore, no  binding was  observed to  PBM 
from normal donors or from patients with chronic lymphocytic leukemia (CLL), 
myeloma, or macroglobulinaemia, or to MNC from normal secondary lymphoid 
tissue. Present evidence thus suggests that KMA may be regarded in an opera- 
tional sense as a tumor marker with specificity for kappa myeloma cells. 
The proportion of plasma cells in the bone marrow that could be labeled with 
K-l-21 varied greatly. On the basis of flow cytometry analysis, this appears to be 
related to the cycling characteristics of the tumor at the time of sampling rather 
than to a true lack of expression of KMA (unpublished observations). Predictably, 
therefore, BJP from the two patients whose bone marrow cells failed to bind K- 
1-21,  but  did  react  with  a  polyvalent anti-kappa  antiserum,  displayed strong 
reactivity with the monoclonal antibody in an indirect RIA. 
Further analysis of KMA expression was carried out with a  panel of human 
cell lines. Convincing cell surface reactivity was only observed in the IgG kappa 
myeloma line HMy2, the one myeloma line included in the panel, whereas cells 
from all  other  lines were negative. The  specificity of binding  of K-l-21  was 
confirmed in inhibition studies with FACS Ill analysis. When HMy2 cells were 
exposed  to  K-l-21  antibody  that  had  been  preincubated with  purified  VOR 
kappa light chains, complete inhibition of binding occurred, whereas no compa- 
rable  diminution  in  fluorescence intensity occurred after  preincubation  with 
equivalent amounts of lambda light chain or with human IgG. 
These results raise the interesting question of the nature of the K-1-21-reactive 
determinant on the cell membrane. Since K-l-21  reacts with kappa light chains 
in free form but not with kappa chains associated with intact Ig molecules, KMA 
may be an epitope on kappa chains inserted as free entities in the cell membrane 
of myeloma cells. Consistent with this interpretation is the demonstration of free 1774  BOUX  ET  AL.  BRIEF  DEFINITIVE REPORT 
light  chains  on  the surface of certain  murine  plasmacytoma cells (6) and  their 
absence on normal mouse spleen cells (7). 
However, it is also possible that  K-l-21  may recognize a  cross-reactive deter- 
minant  on a  molecule other than  free kappa light chains that  is unique  to the 
membrane of kappa myeloma cells. Cross-reactivity of this type has been dem- 
onstrated with a number of monoclonal antibodies (8). 
Summary 
A  monoclonal antibody (K-l-21) raised against a  kappa Bence Jones protein 
exhibits unique binding properties to malignant plasma cells. K-l-21  is an IgG1 
kappa antibody that reacts with human kappa light chains in free form, but shows 
no reactivity with heavy chain-associated kappa light chains. By immunofluores- 
cence, K-l-21 binds to the surface of LICR LON/HMy2 (HMy2) kappa myeloma 
cells and to plasma cells from a majority (8/11) of patients with various types of 
kappa myeloma; it did not bind to the surface of normal cells, nor to malignant 
cells of non-kappa  myeloma origin.  Flow cytometry analysis of K-l-21  binding 
to HMy2 cells indicated that the surface reactivity of K-l-21 could be completely 
inhibited  by preincubation  of the  antibody  with  purified  kappa  light  chains, 
whereas no inhibition occurred after preincubation with lambda chains or intact 
human  IgG. Thus, the epitope recognized by K-l-21 on the cell surface may be 
similar,  if not  identical,  to  the  determinant  recognized  on  soluble free  kappa 
light chains, and constitutes a tumor-associated antigen with selectivity for kappa 
myeloma  cells.  K-l-21  may  therefore  have  clinical  potential  in  patients  with 
kappa myeloma. 
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